Onyx invests in continuous manufacturing; Continuus gets $2M; DEA expands some drug quotas;

> Continuus Pharmaceuticals, a Cambridge, MA-based spinoff from the Novartis-MIT Center for Continuous Manufacturing, has raised $2 million in Series A funding to commercialize its new continuous manufacturing process for small-molecule pharmaceuticals. Report

> ProBioGen AG has a non-exclusive commercial multi-product licensing agreement with Novartis ($NVS) for the Swiss drugmaker to use its GlymaxX Antibody Glyco-Engineering technology to manufacture selected ADCC activity-enhanced antibodies in clinical and preclinical development. Release

> The Drug Enforcement Agency is proposing new manufacturing quotas for some schedule drugs. Report

> The FDA has gotten a conviction and a $60,000 fine for a New York company that sold a weight loss supplement containing the prescription diuretic bumetanide. Release

> Cytovance Biologics has completed the GMP manufacturing of ARMO BioSciences' lead product, a PEGylated form of recombinant human interleukin-10 being studied for use on advanced solid tumors. Report

And Finally... U.K.-based Onyx Scientific is putting continuous manufacturing equipment into its plant in Sunderland to help reduce costs for clients. Report